{"type":"trials","record":{"id":41718,"source_id":"clinicaltrials-gov","external_id":"NCT03197493","title":"Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)","brief_summary":"This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD. This trial is a 9 month extension for patients who successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy. It will use the two higher dose regimens of protocol 0002. these will be assigned according to how well the higher dose was tolerated in protocol 0002.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","enrollment":35,"countries":["United States"],"start_date":"2017-08-01","completion_date":"2020-07-09","last_update_date":"2025-09-12","source_url":"https://clinicaltrials.gov/study/NCT03197493","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":null,"organization":"Snyder, Robert W., M.D., Ph.D., P.C.","interventions":["carbidopa-levodopa 25-100 mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in Best Corrected Visual Acuity by ETDRS Visual Scale Testing — From the start of the study (Visit 1) to the las…","Number of Adverse Events Experienced — Monthly for 9 months","Change in Central Retinal (Macular) Thickness — From the start of the study (Visit 1) to the last completed visit, whet…","Percent Change in Retinal Fluid From Baseline — From the start of the study (Visit 1) to the last completed visit, whet…"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Macula; Degeneration","Retina","carbidopa-levodopa 25-100 mg"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03197493","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2017-08-01 to 2020-07-09","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.858Z","intervention":["carbidopa-levodopa 25-100 mg"],"participants":35,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in Best Corrected Visual Acuity by ETDRS Visual Scale Testing — From the start of the study (Visit 1) to the las…","Number of Adverse Events Experienced — Monthly for 9 months","Change in Central Retinal (Macular) Thickness — From the start of the study (Visit 1) to the last completed visit, whet…","Percent Change in Retinal Fluid From Baseline — From the start of the study (Visit 1) to the last completed visit, whet…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41718","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}